Axon Enterprise Inc vs ClearPoint Neuro Inc — how do they compare? Axon Enterprise Inc trades at $610.01 (market cap $51.69B), while ClearPoint Neuro Inc trades at $14.77 (market cap $454.21M). The key difference: Axon Enterprise Inc is far larger — about 113.8× ClearPoint Neuro Inc's market cap, and Axon Enterprise Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| AXON | CLPT | |
|---|---|---|
Market Cap | $51.69B | $454.21M |
Sector | Technology | Health |
52-Week High | $791.62 | $29.60 |
52-Week Low | $345.94 | $8.66 |
Enterprise Value | $52.83B | $488.79M |
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $616.97, up 3.46% in the last 24 hours, showing strong momentum with a bullish technical signal and consistent earnings beats. The stock is near its pivot point of $629, with support at $616 and resistance at $649. Revenue grew 35% year-over-year in Q2 2026, driven by AI and counter-drone offerings, though high valuation multiples like a P/E of 265.13 and P/S of 16.35 reflect premium pricing. Analyst consensus is strongly bullish with an $685 price target, but gross margin compression and elevated multiples pose risks.
Outlook remains positive given robust growth and AI adoption, but investors face valuation risks and margin pressures. The stock offers upside to consensus targets if execution continues, yet any growth slowdown could trigger significant multiple contraction. Key catalysts include Q3 2026 earnings and AI-driven contract expansions.
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →